Belrapzo (Bendamustine HCl) Patent Expiration, LOE Window & CMS Spending

Belrapzo (Bendamustine HCl) by Eagle: FDA Orange Book LOE 2031-08-11, 0 AB generics, $483K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEagle
FDA Application & PathwayN205580 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-08-11
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$483K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$483K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel